A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Stryker Corporation SYK

Mixed Medical Devices & Diagnostics sector · Stryker — orthopedics, surgical robotics (Mako) and medtech with a deep installed base.

Stryker Corporation (SYK) is an established Medical Devices & Diagnostics company, graded Mixed on FrontierLab's evidence-based quality rubric (data as of 2026-10-05). Revenue grew 8.5% year-over-year at a 65.2% gross margin. Gross-profits-to-assets is 0.35; Rule of 40 is 30.5. Net share issuance -0.1% YoY (flat share count). No risk flags are currently noted. Analyst mix: 27 buy / 7 hold / 0 sell. Track record: 24% of Mixed-graded names beat the S&P over 63 sessions (95% CI 10–47%, N=17). Median excess vs the S&P was -7.2%.

These sentences are generated from the day's data by deterministic templates.

Key quality signals

Revenue growth (YoY)	8.5%
Gross margin	65.2%
Gross profits / assets	0.35
Rule of 40	30.5
Net margin	22%
Cash runway (months)	—
PEG	1
Price / sales	4.1

Quality checklist

Each line is one quality test behind the grade — ✓ passed · ~ borderline · ✗ failed. Hover a metric in the tables below for what it means.

✗ Revenue growth — 8.5% (pass ≥ 20%)
✓ Gross profits / assets — 0.35 (pass ≥ 0.33)
· Rule of 40 — 30.5 (context — graded for software only)
✓ Gross margin — 65.2% (pass ≥ 60% · Medical Devices & Diagnostics)
✓ Cash generation
✓ Share dilution — -0.1%
✓ Competitive moat — Wide
✓ Market size (TAM) — Large

Grade history

Graded Mixed since 2026-06-17 — no grade changes recorded yet.

How have Mixed-graded names performed?

The forward returns of all Mixed-graded names since each grade was recorded — the bucket this name currently sits in, not a forecast of this individual stock.

Window	Forward record vs the S&P	Median
~1 month	28% of Mixed-graded names beat the S&P over 21 sessions (95% CI 12–51%, N=18).	Median excess vs the S&P was -8.2%.
~3 months	24% of Mixed-graded names beat the S&P over 63 sessions (95% CI 10–47%, N=17).	Median excess vs the S&P was -7.2%.
~6 months	building — 46 more sessions needed

Scope: these are forward returns vs the S&P among names still covered at each horizon's end, within the curated universe — not a survivorship-clean whole-market backtest. Names later dropped from coverage are counted as attrition (not hidden), and single-session moves beyond ±300% are treated as split/data artifacts and excluded. How this is measured → · Full track record →

How it compares

Revenue growth: lower than most Medical Devices & Diagnostics peers (N=7)

Gross profits / assets: lower than most Medical Devices & Diagnostics peers (N=7)

Gross margin: lower than most Medical Devices & Diagnostics peers (N=7)

Coarse same-sector, same-stage context — not a percentile or rank. GP/A is graded on its absolute level, not position.

Fundamentals

Market cap	$105.59B
Stage	Established
Share issuance (YoY)	-0.1% · flat share count
Moat	Wide
TAM	LARGE
P/E (trailing)	28.5
EPS (trailing)	$9.65
Burn multiple	—
Gross-margin trend (pts)	3
Cash / assets	0.07
Accruals (%)	-3.8%
Net debt / EBITDA	1.8
Statements as of	Q2 FY2026 · filed 2026-07-31

Momentum context — describes the past, not a signal

52-week range

$267$392.55

Low reached Sep 24, 2026 · high reached Oct 22, 2025 — by daily close.

Price	$275.43 (as of 2026-10-02)
Last session move	—
% off 52-wk high	-29.8%
RSI (14)	38
Relative volume	0.6×

Insider activity (90 days)

Cluster buyers	0
Sellers	3

Insider selling is routine diversification, not a bearish signal.

Analyst mix

Strong buy	12
Buy	15
Hold	7
Sell	0
Strong sell	0

Ratings are context, not a price target. "Momentum" = how the mix changed over recent weeks, not a forecast.

From the headlines

Stryker positioned among AI healthcare stocks with earnings growth potential versus valuation peers.

GEHC vs. SYK: Which Stock Should Value Investors Buy Now?

AI take — daily, AI-generated

AI leans mixed

Moderate 8.5% growth at a reasonable PEG of 1.0 is fair but uninspiring; the AI healthcare narrative is interesting but not yet proven in earnings.

Generated by an AI model from the day's news — an opinion for context only. Not financial advice, not a recommendation, and not a price target.

Similar Medical Devices & Diagnostics names

Intuitive Surgical, Inc.Boston Scientific CorporationEdwards Lifesciences CorporationDexCom, Inc.IDEXX Laboratories, Inc.Insulet Corp.

← All Medical Devices & Diagnostics names · Open SYK in the interactive screener →

Data as of 2026-10-05 08:19 (end-of-day). How grades are computed →